Literature DB >> 27174880

Predictive and prognostic factors in patients with blood-culture-positive community-acquired pneumococcal pneumonia.

Rosanel Amaro1, Adamantia Liapikou2, Catia Cilloniz1, Albert Gabarrus1, Francesc Marco3, Jacobo Sellares1, Eva Polverino1, Javier Garau4, Miquel Ferrer1, Daniel M Musher5, Antoni Torres6.   

Abstract

In patients with pneumococcal community-acquired pneumonia (CAP), the risk factors for bacteraemia and its impact on outcomes are not fully elucidated. We aimed to compare characteristics of patients with blood-culture-positive versus blood-culture-negative pneumococcal CAP, and to characterise bacteraemic serotypes.We describe a prospective, observational study on nonimmunocompromised patients with pneumococcal CAP, from 1996 to 2013. We define severe pneumonia according to American Thoracic Society/Infectious Diseases Society of America guidelines.Of a total of 917 patients with pneumococcal CAP, 362 had blood-culture-positive pneumococcal pneumonia (BCPPP; 39%). High C-reactive protein (CRP) (≥20 mg·dL(-1)) (odds ratio (OR) 2.36, 95% CI 1.45-3.85), pleural effusion (OR 2.03, 95% CI 1.13-3.65) and multilobar involvement (OR 1.69, 95% CI 1.02-2.79) were independently associated with bacteraemic CAP, while nursing home resident (OR 0.12, 95% CI 0.01-1.00) was found as a protective factor. Despite the clinical differences, BCPPP showed similar outcomes to blood-culture-negative pneumococcal pneumonia (BCNPP). 14% of the serotypes (period 2006-2013) causing bacteraemia are included in pneumococcal conjugate vaccine PVC7, 74% in pneumococcal conjugate vaccine PVC13 and 83% in pneumococcal polysaccharide vaccine PPSV23.Pleural effusion, a high level of CRP and multilobar involvement predicted an increased risk of BCPPP. Although BCPPP patients were more severely ill at admission, mortality was not significantly greater than in BCNPP patients.
Copyright ©ERS 2016.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27174880     DOI: 10.1183/13993003.00039-2016

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  11 in total

Review 1.  Year in review 2016: Respiratory infections, acute respiratory distress syndrome, pleural diseases, lung cancer and interventional pulmonology.

Authors:  Marcos I Restrepo; James D Chalmers; Yuanlin Song; Christopher Mallow; Justin Hewlett; Fabien Maldonado; Lonny Yarmus
Journal:  Respirology       Date:  2017-02-28       Impact factor: 6.424

2.  Relationship between serotypes, disease characteristics and 30-day mortality in adults with invasive pneumococcal disease.

Authors:  Jacques Gaillat; Amine Benadji; Xavier Duval; Kostas Danis; Bruno Hoen; Bernard Page; Guillaume Béraud; Véronique Vernet-Garnier; Christophe Strady; Nathalie Brieu; Laurence Maulin; Carine Roy; Marie-Cécile Ploy; Emmanuelle Varon; Sarah Tubiana
Journal:  Infection       Date:  2021-09-01       Impact factor: 3.553

3.  C-type Lectin Mincle Recognizes Glucosyl-diacylglycerol of Streptococcus pneumoniae and Plays a Protective Role in Pneumococcal Pneumonia.

Authors:  Friederike Behler-Janbeck; Tomotsugu Takano; Regina Maus; Jennifer Stolper; Danny Jonigk; Meritxell Tort Tarrés; Thomas Fuehner; Antje Prasse; Tobias Welte; Mattie S M Timmer; Bridget L Stocker; Yoichi Nakanishi; Tomofumi Miyamoto; Sho Yamasaki; Ulrich A Maus
Journal:  PLoS Pathog       Date:  2016-12-06       Impact factor: 6.823

4.  Time to blood culture positivity as a predictor of clinical outcomes and severity in adults with bacteremic pneumococcal pneumonia.

Authors:  Catia Cillóniz; Adrian Ceccato; Cristina de la Calle; Albert Gabarrús; Carolina Garcia-Vidal; Manel Almela; Alex Soriano; José Antonio Martinez; Francesc Marco; Jordi Vila; Antoni Torres
Journal:  PLoS One       Date:  2017-08-07       Impact factor: 3.240

5.  IL-36γ is a crucial proximal component of protective type-1-mediated lung mucosal immunity in Gram-positive and -negative bacterial pneumonia.

Authors:  M A Kovach; B Singer; G Martinez-Colon; M W Newstead; X Zeng; P Mancuso; T A Moore; S L Kunkel; M Peters-Golden; B B Moore; T J Standiford
Journal:  Mucosal Immunol       Date:  2017-02-08       Impact factor: 7.313

6.  White Blood Cell Counts, Alcoholism, and Cirrhosis in Pneumococcal Pneumonia.

Authors:  Julianna G Gardner; Divya R Bhamidipati; Adriana M Rueda; Duc T M Nguyen; Edward A Graviss; Daniel M Musher
Journal:  Open Forum Infect Dis       Date:  2017-02-24       Impact factor: 3.835

7.  Oral versus intravenous clarithromycin in moderate to severe community-acquired pneumonia: an observational study.

Authors:  Nikolas Rae; Aran Singanayagam; Stuart Schembri; James D Chalmers
Journal:  Pneumonia (Nathan)       Date:  2017-02-05

8.  Guidelines vs Actual Management of Skin and Soft Tissue Infections in the Emergency Department.

Authors:  Rahul S Kamath; Deepthi Sudhakar; Julianna G Gardner; Vagish Hemmige; Hossam Safar; Daniel M Musher
Journal:  Open Forum Infect Dis       Date:  2018-01-12       Impact factor: 3.835

9.  A model for predicting bacteremia in patients with community-acquired pneumococcal pneumonia: a retrospective observational study.

Authors:  Yasuyoshi Washio; Akihiro Ito; Shogo Kumagai; Tadashi Ishida; Akio Yamazaki
Journal:  BMC Pulm Med       Date:  2018-01-30       Impact factor: 3.317

Review 10.  Community-acquired bacterial pneumonia in adults: An update.

Authors:  Vandana Kalwaje Eshwara; Chiranjay Mukhopadhyay; Jordi Rello
Journal:  Indian J Med Res       Date:  2020-04       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.